FREDERICK, Md., Sept. 28, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced neuromodulationmedical devices announced that it has submitted a paper: "ActiPatch© Central Sensitization Therapy: A Chronic Back Pain Registry Study of Pain Relief & Analgesic Adverse Effects" for publication. The study reports that the majority of chronic back
The Company's prior research published in Pain Management of 5,000+ users' results A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy, Pain Manag. 2015 Nov; 5(6): 413-23, http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35, was one of the Top 5 articles read out of all of the 28 Future Science Group Journals in 2106. Future Science Group is a progressive publisher focused on breakthrough medical biotechnological and scientific research.
About BioElectronics CorporationBioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.
Contact:Grace Holdings 732-335-1152
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bioelectronics-submits-back-pain-relief--medication-use-side-effects-registry-study-for-publication-300335240.html
SOURCE BioElectronics Corporation
Subscribe to our Free Newsletters!
Learn the basics about diabetes and how to bring it under control with turmeric, an highly ...
Antioxidants are artificial or natural components that help protect the human body from the damage ...
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...View All